Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
459 In first-line treatment of metastatic TNBC, the anti-PD-L1/CTLA-4 bispecific antibody KN046, combined with nab-paclitaxel, shows significant efficacy and survival benefits
No Publication available at this time.
The weight-lowering effect is likely mediated by enhanced energy expenditure 23 , modulation of the gut microbiota leading to increased fecal energy excretion 24 , and fermentation of dietary fiber into SCFAs, which promote lipid oxidation and suppress systemic lipogenesis 25
This makes combination therapy more effective and improves health outcomes
US$ 21.43
US$ 29.33
US$ 24.82
US$ 26.44
